Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Dong, Jun ^a   Zeng, Bo Hang ^a   Xu, Li Hua ^b   Wang, Jun Ye ^b   Li, Man Zhi ^b   Zeng, Mu Sheng ^b   Liu, Wan Li ^b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CARCINOEMBRYONIC ANTIGEN; CDC25B AUTOANTIBODY; CYTOKERATIN 19 FRAGMENT; SQUAMOUS CELL CARCINOMA ANTIGEN; UNCLASSIFIED DRUG; ANTIGEN CYFRA21.1; CDC25B PROTEIN, HUMAN; CYTOKERATIN 19; PROTEIN TYROSINE PHOSPHATASE; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA RELATED ANTIGEN; SQUAMOUS CELL CARCINOMA-RELATED ANTIGEN; TUMOR ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; BLOOD; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS TUMOR; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; AUTOANTIBODIES; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CDC25 PHOSPHATASES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KERATIN-19; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SERPINS;

EID: 77956482691     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-81     Document Type: Article

References (38)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003, 349:2241-2252. 10.1056/NEJMra035010, 14657432.
2. Lerut T, Coosemans W, De Leyn P, Van Raemdonck D, Deneffe G, Decker G. Treatment of esophageal carcinoma. Chest 1999, 116:463S-465S. 10.1378/chest.116.suppl_3.463S, 10619509.
3. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, Kobayashi S, Hayashi H, Ochiai T. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 2003, 133:486-494. 10.1067/msy.2003.139, 12773976.
4. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997, 80:1803-1804. 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9, 9351551.
5. Ralhan R, Arora S, Chattopadhyay TK, Shukla NK, Mathur M. Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer 2000, 85:791-795. 10.1002/(SICI)1097-0215(20000315)85:6<791::AID-IJC9>3.0.CO;2-K, 10709097.
6. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Shiratori T, Hayashi H, Takeda A, Ochiai T. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery 2002, 132:41-47. 10.1067/msy.2002.125307, 12110794.
7. Takahashi K, Miyashita M, Nomura T, Makino H, Futami R, Kashiwabara M, Katsuta M, Tajiri T. Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma. Dis Esophagus 2007, 20:117-122. 10.1111/j.1442-2050.2007.00656.x, 17439594.
8. Shimada H, Kuboshima M, Shiratori T, Nabeya Y, Takeuchi A, Takagi H, Nomura F, Takiguchi M, Ochiai T, Hiwasa T. Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol 2007, 30:97-103.
9. Kuboshima M, Shimada H, Liu TL, Nomura F, Takiguchi M, Hiwasa T, Ochiai T. Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Sci 2006, 97:380-6. 10.1111/j.1349-7006.2006.00192.x, 16630135.
10. Fujita Y, Nakanishi T, Miyamoto Y, Hiramatsu M, Mabuchi H, Miyamoto A, Shimizu A, Takubo T, Tanigawa N. Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett 2008, 263:280-290. 10.1016/j.canlet.2008.01.013, 18334280.
11. Shimada H, Nakashima K, Ochiai T, Nabeya Y, Takiguchi M, Nomura F, Hiwasa T. Serological identification of tumor antigens of esophageal squamous cell carcinoma. Int J Oncol 2005, 26:77-86.
12. Liu WL, Zhang G, Wang JY, Cao JY, Guo XZ, Xu LH, Li MZ, Song LB, Huang WL, Zeng MS. Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma. Biochem Biophys Res Commun 2008, 375:440-445. 10.1016/j.bbrc.2008.08.039, 18722351.
13. Nilsson I, Hoffmann I. Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res 2000, 4:107-114.
14. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, Beach D. CDC25 phosphatases as potential human oncogenes. Science 1995, 269:1575-1577. 10.1126/science.7667636, 7667636.
15. Cangi MG, Cukor B, Soung P, Signoretti S, Moreira G, Ranashinge M, Cady B, Pagano M, Loda M. Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest 2000, 106:753-761. 10.1172/JCI9174, 381390, 10995786.
16. Mailand N, Podtelejnikov AV, Groth A, Mann M, Bartek J, Lukas J. Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. Embo J 2002, 21:5911-5920. 10.1093/emboj/cdf567, 131064, 12411508.
17. Takemasa I, Yamamoto H, Sekimoto M, Ohue M, Noura S, Miyake Y, Matsumoto T, Aihara T, Tomita N, Tamaki Y, et al. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Cancer Res 2000, 60:3043-3050.
18. Ito Y, Yoshida H, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Nakamura Y, et al. Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis. Cancer Lett 2005, 229:291-297. 10.1016/j.canlet.2005.06.040, 16095809.
19. Kristjansdottir K, Rudolph J. Cdc25 phosphatases and cancer. Chem Biol 2004, 11:1043-1051. 10.1016/j.chembiol.2004.07.007, 15324805.
20. Hernandez S, Hernandez L, Bea S, Cazorla M, Fernandez PL, Nadal A, Muntane J, Mallofre C, Montserrat E, Cardesa A, Campo E. cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin's lymphomas. Cancer Res 1998, 58:1762-1767.
21. Sasaki H, Yukiue H, Kobayashi Y, Tanahashi M, Moriyama S, Nakashima Y, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y. Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer. Cancer Lett 2001, 173:187-192. 10.1016/S0304-3835(01)00669-3, 11597794.
22. Nishioka K, Doki Y, Shiozaki H, Yamamoto H, Tamura S, Yasuda T, Fujiwara Y, Yano M, Miyata H, Kishi K, Nakagawa H, Shamma A, Monden M. Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus. Br J Cancer 2001, 85:412-21. 10.1054/bjoc.2001.1934, 2364065, 11487274.
23. Hu YC, Lam KY, Law S, Wong J, Srivastava G. Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC. Clin Cancer Res 2001, 7:2213-2221.
24. Xue LY, Hu N, Song YM, Zou SM, Shou JZ, Qian LX, Ren LQ, Lin DM, Tong T, He ZG, Zhan QM, Taylor PR, Lu N. Tissue microarray analysis reveals a tight correlation between protein expression pattern and progression of esophageal squamous cell carcinoma. BMC Cancer 2006, 6:296. 10.1186/1471-2407-6-296, 1766359, 17187659.
25. Shou JZ, Hu N, Takikita M, Roth MJ, Johnson LL, Giffen C, Wang QH, Wang C, Wang Y, Su H, et al. Overexpression of CDC25B and LAMC2 mRNA and protein in esophageal squamous cell carcinomas and premalignant lesions in subjects from a high-risk population in China. Cancer Epidemiol Biomarkers Prev 2008, 17:1424-1435. 10.1158/1055-9965.EPI-06-0666, 2729558, 18559558.
26. Zhang H, Jin Y, Chen X, Jin C, Law S, Tsao SW, Kwong YL. Cytogenetic aberrations in immortalization of esophageal epithelial cells. Cancer genetics and cytogenetics 2006, 165:25-35. 10.1016/j.cancergencyto.2005.07.016, 16490594.
27. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006, 66:6225-6232. 10.1158/0008-5472.CAN-06-0094, 16778197.
28. Guo XZ, Zhang G, Wang JY, Liu WL, Wang F, Dong JQ, Xu LH, Cao JY, Song LB, Zeng MS. Prognostic relevance of Centromere protein H expression in esophageal carcinoma. BMC Cancer 2008, 8:233. 10.1186/1471-2407-8-233, 2535782, 18700042.
29. Finn OJ. Immune response as a biomarker for cancer detection and a lot more. N Engl J Med 2005, 353:1288-1290. 10.1056/NEJMe058157, 16177255.
30. Mealy K, Feely J, Reid I, McSweeney J, Walsh T, Hennessy TP. Tumour marker detection in oesophageal carcinoma. Eur J Surg Oncol 1996, 22:505-507. 10.1016/S0748-7983(96)92998-4, 8903494.
31. Munck-Wikland E, Kuylenstierna R, Wahren B, Lindholm J, Haglund S. Tumor markers carcinoembryonic antigen, CA 50, and CA 19-9 and squamous cell carcinoma of the esophagus. Pretreatment screening. Cancer 1988, 62:2281-2286. 10.1002/1097-0142(19881201)62:11<2281::AID-CNCR2820621102>3.0.CO;2-1, 3179942.
32. Yi Y, Li B, Wang Z, Sun H, Gong H, Zhang Z. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Biomarkers 2009, 14:480-485. 10.3109/13547500903180265, 19863186.
33. Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, Suzuki T. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 1997, 79:1647-1655. 10.1002/(SICI)1097-0142(19970501)79:9<1647::AID-CNCR3>3.0.CO;2-9, 9128978.
34. Chen W, Abnet CC, Wei WQ, Roth MJ, Lu N, Taylor PR, Pan QJ, Luo XM, Dawsey SM, Qiao YL. Serum markers as predictors of esophageal squamous dysplasia and early cancer. Anticancer Res 2004, 24:3245-3249.
35. Ehrlich JR, Qin S, Liu BC. The 'reverse capture' autoantibody microarray: a native antigen-based platform for autoantibody profiling. Nat Protoc 2006, 1:452-460. 10.1038/nprot.2006.66, 17406268.
36. Ehrlich JR, Tang L, Caiazzo RJ, Cramer DW, Ng SK, Ng SW, Liu BC. The "reverse capture" autoantibody microarray: an innovative approach to profiling the autoantibody response to tissue-derived native antigens. Methods Mol Biol 2008, 441:175-192. full_text, 18370319.
37. Qin S, Qiu W, Ehrlich JR, Ferdinand AS, Richie JP, O'Leary MP, Lee ML, Liu BC. Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling. Proteomics 2006, 6:3199-3209. 10.1002/pmic.200500673, 16596707.
38. Miyata H, Doki Y, Shiozaki H, Inoue M, Yano M, Fujiwara Y, Yamamoto H, Nishioka K, Kishi K, Monden M. CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin Cancer Res 2000, 6:4859-4865.